 Meredith Tennis
Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2025 | 2664 | 2.840 |
Why?
| | Iloprost | 8 | 2023 | 45 | 2.390 |
Why?
| | Frizzled Receptors | 4 | 2022 | 25 | 1.580 |
Why?
| | Epoprostenol | 5 | 2021 | 132 | 1.550 |
Why?
| | Precancerous Conditions | 5 | 2025 | 166 | 1.430 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 7 | 2024 | 1189 | 1.290 |
Why?
| | Urethane | 5 | 2025 | 43 | 1.170 |
Why?
| | Smoke | 4 | 2020 | 148 | 1.030 |
Why?
| | Wnt Proteins | 4 | 2012 | 133 | 0.930 |
Why?
| | MicroRNAs | 2 | 2022 | 686 | 0.760 |
Why?
| | Cigarette Smoking | 1 | 2022 | 102 | 0.630 |
Why?
| | Lung | 8 | 2025 | 4106 | 0.600 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2010 | 231 | 0.590 |
Why?
| | Hydrogels | 2 | 2025 | 701 | 0.570 |
Why?
| | PPAR gamma | 4 | 2022 | 178 | 0.570 |
Why?
| | Chemoprevention | 3 | 2023 | 92 | 0.540 |
Why?
| | Anticarcinogenic Agents | 1 | 2018 | 62 | 0.540 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2010 | 337 | 0.530 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2022 | 219 | 0.520 |
Why?
| | Intracellular Signaling Peptides and Proteins | 3 | 2021 | 456 | 0.450 |
Why?
| | Epithelial Cells | 5 | 2022 | 1131 | 0.380 |
Why?
| | Mice | 11 | 2025 | 18329 | 0.380 |
Why?
| | Nerve Tissue Proteins | 2 | 2021 | 591 | 0.370 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 36 | 0.350 |
Why?
| | Carcinogens | 3 | 2022 | 123 | 0.340 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2022 | 641 | 0.340 |
Why?
| | Antihypertensive Agents | 2 | 2017 | 519 | 0.330 |
Why?
| | Cell Migration Inhibition | 1 | 2010 | 16 | 0.320 |
Why?
| | Growth Inhibitors | 1 | 2010 | 39 | 0.320 |
Why?
| | Signal Transduction | 5 | 2010 | 5216 | 0.300 |
Why?
| | Animals | 12 | 2025 | 38030 | 0.280 |
Why?
| | Neoplasms, Second Primary | 1 | 2009 | 102 | 0.280 |
Why?
| | Glycoproteins | 1 | 2010 | 354 | 0.270 |
Why?
| | Bronchi | 3 | 2018 | 263 | 0.260 |
Why?
| | Adenocarcinoma | 2 | 2017 | 925 | 0.260 |
Why?
| | Neoplasms, Experimental | 2 | 2018 | 167 | 0.250 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2597 | 0.250 |
Why?
| | Smoking | 2 | 2012 | 1472 | 0.250 |
Why?
| | DNA Methylation | 1 | 2012 | 674 | 0.250 |
Why?
| | Cell Movement | 1 | 2010 | 959 | 0.230 |
Why?
| | Breast Neoplasms | 3 | 2021 | 2382 | 0.210 |
Why?
| | Mice, Transgenic | 3 | 2018 | 2188 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2022 | 3542 | 0.190 |
Why?
| | Registries | 2 | 2009 | 2406 | 0.170 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 61 | 0.160 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4560 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 135 | 0.160 |
Why?
| | Carmustine | 1 | 2020 | 52 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2021 | 89 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 171 | 0.160 |
Why?
| | Protein Domains | 1 | 2022 | 311 | 0.160 |
Why?
| | Carcinogenesis | 1 | 2021 | 228 | 0.150 |
Why?
| | Respiratory System | 1 | 2020 | 150 | 0.150 |
Why?
| | Cell Line | 2 | 2018 | 2823 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2022 | 820 | 0.140 |
Why?
| | Tobacco Smoking | 1 | 2018 | 27 | 0.140 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2018 | 65 | 0.140 |
Why?
| | Tobacco Smoke Pollution | 1 | 2020 | 227 | 0.140 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2018 | 161 | 0.130 |
Why?
| | Protein Binding | 1 | 2022 | 2238 | 0.110 |
Why?
| | Humans | 16 | 2024 | 145474 | 0.110 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5983 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2021 | 4148 | 0.090 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2012 | 16 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1716 | 0.090 |
Why?
| | Cell Proliferation | 3 | 2018 | 2507 | 0.090 |
Why?
| | Desmoglein 3 | 2 | 2022 | 14 | 0.080 |
Why?
| | Azacitidine | 1 | 2012 | 157 | 0.080 |
Why?
| | Luciferases | 1 | 2010 | 153 | 0.080 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2009 | 16 | 0.080 |
Why?
| | Mesoderm | 1 | 2010 | 147 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2022 | 2803 | 0.070 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 506 | 0.070 |
Why?
| | Tumor Cells, Cultured | 1 | 2010 | 886 | 0.070 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 151 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 977 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2010 | 321 | 0.070 |
Why?
| | Blotting, Western | 1 | 2010 | 1179 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2009 | 330 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1246 | 0.060 |
Why?
| | Biomarkers | 1 | 2018 | 4295 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2009 | 688 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2878 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2018 | 11772 | 0.060 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2005 | 100 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2009 | 740 | 0.050 |
Why?
| | Disease Progression | 2 | 2024 | 2864 | 0.050 |
Why?
| | Phenotype | 1 | 2012 | 3155 | 0.050 |
Why?
| | Keratin-5 | 1 | 2022 | 44 | 0.050 |
Why?
| | Formaldehyde | 1 | 2022 | 65 | 0.050 |
Why?
| | Algorithms | 1 | 2009 | 1845 | 0.040 |
Why?
| | Tubulin | 1 | 2022 | 146 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1734 | 0.040 |
Why?
| | Lung Diseases | 1 | 2008 | 780 | 0.040 |
Why?
| | Mice, Inbred A | 1 | 2020 | 48 | 0.040 |
Why?
| | Immunoblotting | 1 | 2021 | 295 | 0.040 |
Why?
| | Prognosis | 1 | 2009 | 4316 | 0.040 |
Why?
| | Female | 7 | 2022 | 78844 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 899 | 0.040 |
Why?
| | gamma Catenin | 1 | 2018 | 13 | 0.040 |
Why?
| | Metaplasia | 1 | 2018 | 57 | 0.030 |
Why?
| | Bronchial Diseases | 1 | 2018 | 38 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2018 | 97 | 0.030 |
Why?
| | Receptors, Prostaglandin | 1 | 2017 | 21 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 145 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 91 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 196 | 0.030 |
Why?
| | Aged | 3 | 2018 | 26153 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 624 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1082 | 0.030 |
Why?
| | Middle Aged | 3 | 2018 | 36215 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 630 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1507 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1443 | 0.020 |
Why?
| | Drug Design | 1 | 2008 | 175 | 0.020 |
Why?
| | United States | 1 | 2024 | 16098 | 0.020 |
Why?
| | Cobalt Radioisotopes | 1 | 2005 | 7 | 0.010 |
Why?
| | Cocarcinogenesis | 1 | 2005 | 13 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 2005 | 86 | 0.010 |
Why?
| | Radiotherapy Dosage | 1 | 2005 | 288 | 0.010 |
Why?
| | Radiotherapy | 1 | 2005 | 204 | 0.010 |
Why?
| | Odds Ratio | 1 | 2005 | 1082 | 0.010 |
Why?
| | Adult | 1 | 2018 | 40777 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 7123 | 0.010 |
Why?
| | Risk Factors | 1 | 2005 | 10885 | 0.010 |
Why?
| | Male | 1 | 2018 | 72842 | 0.010 |
Why?
|
|
Tennis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|